ABEONA THERAPEUT. DL-01 Asset Resilience Ratio

Latest as of December 2025: 51.45%

ABEONA THERAPEUT. DL-01 asset resilience ratio. ABEONA THERAPEUT. DL-01 (PCJ) has an Asset Resilience Ratio of 51.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of ABEONA THERAPEUT. DL-01 to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€112.97 Million
≈ $132.07 Million USD Cash + Short-term Investments

Total Assets

€219.57 Million
≈ $256.70 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of ABEONA THERAPEUT. DL-01 (2021–2025)

Asset resilience ratio of ABEONA THERAPEUT. DL-01 from 2021 to 2025. This chart shows how ABEONA THERAPEUT. DL-01's Asset Resilience Ratio has changed over time. Read PCJ total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down ABEONA THERAPEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ABEONA THERAPEUT. DL-01 asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €112.97 Million 51.45%
Total Liquid Assets €112.97 Million 51.45%

Asset Resilience Insights

  • Very High Liquidity: ABEONA THERAPEUT. DL-01 maintains exceptional liquid asset reserves at 51.45% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ABEONA THERAPEUT. DL-01 Industry Peers by Asset Resilience Ratio

Compare ABEONA THERAPEUT. DL-01's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

ABEONA THERAPEUT. DL-01 Asset Resilience Ratio by Year (2021–2025)

ABEONA THERAPEUT. DL-01 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ABEONA THERAPEUT. DL-01.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 51.45% €112.97 Million
≈ $132.07 Million
€219.57 Million
≈ $256.70 Million
-16.82pp
2024-12-31 68.27% €74.36 Million
≈ $86.94 Million
€108.93 Million
≈ $127.35 Million
+9.28pp
2023-12-31 58.99% €37.75 Million
≈ $44.14 Million
€64.00 Million
≈ $74.83 Million
-0.08pp
2022-12-31 59.07% €37.93 Million
≈ $44.35 Million
€64.21 Million
≈ $75.07 Million
+43.89pp
2021-12-31 15.19% €12.09 Million
≈ $14.13 Million
€79.59 Million
≈ $93.04 Million
--
pp = percentage points

About ABEONA THERAPEUT. DL-01

F:PCJ Germany Biotechnology
Market Cap
$256.10 Million
€219.05 Million EUR
Market Cap Rank
#15288 Global
#1499 in Germany
Share Price
€3.85
Change (1 day)
-3.89%
52-Week Range
€3.56 - €6.36
All Time High
€17.73
About

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more